Atrium (RNA) CEO Kathleen Gallagher Withholds 11,632 Shares for Taxes

What Happened

Kathleen P. Gallagher, CEO and President of Atrium Therapeutics, had 11,632 shares withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). The shares were valued at $8.95 each, for a total of approximately $104,106. This was a non-market disposition (tax withholding), not an open-market sale.

Key Details

• Transaction date: 2026-09-18
• Price per share: $8.95; Total value: ~$104,106
• Transaction code: F (shares withheld to satisfy tax withholding on vesting) — footnote confirms issuer withheld shares to cover taxes on RSUs.
• Shares owned after transaction: Not reported in the provided filing excerpt.
• Filing date: 2026-09-22 — filing appears timely (within the SEC’s two-business-day Form 4 deadline for a 9/18 transaction).
• Remarks: Insider listed as Chief Executive Officer and President.

Context

This is a routine tax-withholding event tied to RSU vesting (a cashless method where the company retains a portion of vested shares to cover taxes). Such withholdings are common and do not necessarily indicate a change in insider sentiment about the company’s outlook.